Lenalidomide Launch Kicks Off A Year Of Revlimid Competition
UK Generic Launch Comes Ahead Of Expected Rivals Elsewhere In Europe And US
Accord has confirmed the launch of a generic lenalidomide rival to Revlimid in the UK. The launch leads off a year that is expected to see the BMS blockbuster also face significant competition elsewhere in Europe and the US.
You may also be interested in...
Bristol executives reiterated the company’s aggressive revenue growth expectations while outlining the impact Revlimid generics will have in Europe, Japan and – to a limited extent – in the US.
Further launches of generic lenalidomide rivals to Celgene’s Revlimid have been confirmed in Canada by Apotex and Sandoz.
Mylan is taking aim at a lucrative oral solid formulation in Europe, with the European Medicines Agency’s Committee for Medicinal Products for Human Use recommending approval for the company’s generic version of Revlimid (lenalidomide) capsules.